Zhu Zhou

Dr. Zhu Zhou


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
YTYifang Tang
Yifang Tang
TLTao Liu
Tao Liu
SSShibo Sun
Shibo Sun
YPYoubo Peng
Youbo Peng
XHXiaoxiao Huang
Xiaoxiao Huang
ZZZhu Zhou
Zhu Zhou
GDF-15 is an essential member of the transforming growth factor-beta superfamily. Its functions mainly involve in tissue injury, inflammation, fibrosis, regulation of appetite and weight, development of tumor, and cardiovascular disease. GDF-15 is involved in various signaling pathways, such as MAPK pathway, PI3K/AKT pathway, STAT3 pathway, RET pathway, and SMAD pathway. In addition, several factors such as p53, ROS, and TNF-α participate the regulation of GDF-15. However, the specific mechanism of these factors regulating GDF-15 is still unclear and more research is needed to explore them. GDF-15 mainly improves the function of kidneys in CKD and plays an important role in the prediction of CKD progression and cardiovascular complications. In addition, the role of GDF-15 in the kidney may be related to the SMAD and MAPK pathways. However, the specific mechanism of these pathways remains unclear. Accordingly, more research on the specific mechanism of GDF-15 affecting kidney disease is needed in the future. In conclusion, GDF-15 may be a therapeutic target for kidney disease.

20 July 2021 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
ZZZhiting Zhang
Zhiting Zhang
SWShuguo Wang
Shuguo Wang
LDLingli Du
Lingli Du
LXLing Xu
Ling Xu
YLYu Lin
Yu Lin
JWJianhong Wang
Jianhong Wang

21 September 2022 in Pregnancy Hypertension
Verified
Journal Article
Closed access
YJYuxin Jiang
Yuxin Jiang
WJWenyan Jiang
Wenyan Jiang
YLYuejia Li
Yuejia Li
WGWeinan Gu
Weinan Gu
HHHongdi Huang
Hongdi Huang
ZZZhu Zhou
Zhu Zhou

31 October 2025 in Journal of Ultrasound
Verified
Journal Article
Open access
PDF file
YLYao Li
Yao Li
CYChuanxiong Yang
Chuanxiong Yang
ZZZhu Zhou
Zhu Zhou
Kidney diseases are diverse, with complex pathological mechanisms, and often lack specific clinical symptoms in the early stage. Conventional laboratory or imaging tests are unable to reflect the early pathological changes in the kidney, which often delays the diagnosis and treatment of the disease. In recent years, ultrasound localization microscopy (ULM) has received extensive attention in basic and translational research of renal diseases owing to its unique capability of assessing renal microvascular architecture and function, together with its advantages of high resolution, high penetrability, and real-time imaging. In this paper, we systematically review the research progress of ULM in the diagnosis and treatment of renal diseases, focusing on its potential application in renal microvascular super-resolution imaging, early lesion identification and assisted renal biopsy, and discussing the potential value of ULM in the future precision medicine of renal diseases.

30 September 2025 in Journal of International Medical Research
Verified
Journal Article
Open access
YLYao Li
Yao Li
CYChuanxiong Yang
Chuanxiong Yang
ZZZhu Zhou
Zhu Zhou
Background and objective: Icodextrin is a novel, potentially advantageous peritoneal dialysis solution characterized by low glucose content and high molecular weight. This study aimed to compare the impact of icodextrin and glucose solutions on peritoneal dialysis patients. Methods: This multicenter, prospective, randomized controlled trial included 40 peritoneal dialysis patients. Participants were randomized in a 1:1 ratio into an experimental group (icodextrin group) and a control group (glucose group). Both groups used 1.5% or 2.5% glucose dialysis solutions for three daytime exchanges. At night, the icodextrin group used 7.5% icodextrin, while the glucose group used 2.5% glucose solution. Patients were followed up bimonthly, assessing nighttime ultrafiltration, electrolytes, lipid and glucose profiles, albumin levels, and quality of life using the short form-36 health survey scale at 4 months. Results: After 2 and 4 months, the icodextrin group demonstrated a considerably greater nighttime net ultrafiltration than the glucose group (P < 0.05). After 4 months, the icodextrin group exhibited lower serum sodium, chloride, and systolic blood pressure levels but higher calcium levels, albumin levels, and short form-36 health survey scores than the glucose group (P < 0.05). Conclusions: Icodextrin enhances ultrafiltration, maintains electrolyte balance, and improves nutritional status in peritoneal dialysis patients. These effects contribute toward improvement in the patients’ quality of life. The protocol was registered at chictr.org.cn (Registration Number: ChiCTR2200062379).

13 August 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SWShen Wang
Shen Wang
YHYu He
Yu He
XGXin Gan
Xin Gan
HKHao Kang
Hao Kang
ZZZhu Zhou
Zhu Zhou
ZHZongHai He
ZongHai He
Background: Renal fibrosis is a common pathological outcome of chronic kidney disease and is characterized by persistent profibrotic signaling and impaired cellular homeostasis. Genkwanin (GAK), a natural flavonoid compound, has shown anti-inflammatory and antioxidant activities in several disease models. However, its role in renal fibrosis remains unclear. Materials and methods: We investigated the antifibrotic effects of GAK in a TGF-β1–induced HK-2 cell model and a unilateral ureteral obstruction (UUO) mouse model. EMT- and fibrosis-related changes were assessed by RT-qPCR, Western blotting, immunofluorescence, and histological staining. The involvement of TGF-β1/SMAD2 and β-catenin signaling was examined using pharmacological modulators. Autophagic flux was evaluated by tandem mCherry-GFP-LC3 analysis, transmission electron microscopy, and autophagy-related protein expression. TFEB inhibition was used to further assess the role of lysosome–autophagy regulation. Results: GAK significantly attenuated TGF-β1–induced EMT and extracellular matrix accumulation in HK-2 cells and reduced renal fibrotic injury in UUO mice. Mechanistically, GAK decreased p-SMAD2 expression and limited β-catenin nuclear redistribution, indicating suppression of both TGF-β1/SMAD2 and β-catenin signaling. In addition, GAK improved autophagic flux and increased TFEB expression. Inhibition of TFEB partially weakened the protective effects of GAK on fibrosis-related and autophagy-related changes, suggesting that TFEB-mediated lysosome–autophagy function contributes to its antifibrotic action. Conclusion: In conclusion, GAK alleviates renal fibrosis in vitro and in vivo , at least in part, by suppressing TGF-β1/SMAD2 and β-catenin signaling and by restoring TFEB-associated autophagic flux.